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Abstract 
 
Widespread use of Ganciclovir (GCV) therapy has led to resistant strains of 
cytomegalovirus (CMV), prompting development of new antiviral compounds.  A novel 
duplex compound of Zidovudine and Foscarnet (N3) has shown excellent in-vitro activity 
against both GCV sensitive and resistant HCMV strains.  To begin in-vivo efficacy 
studies, we chose to use a well-characterized murine model of CMV (MCMV) infection.  
We confirmed in-vitro activity of N3 against MCMV using infected fibroblasts.  QRT-
PCR demonstrated that N3 controlled in-vitro DNA replication at 48 or 72hrs pi.  To test 
in-vivo efficacy,  cohorts of BALB/c mice infected with 5 X 104 PFU Smith strain 
MCMV received daily intraperitoneal dosing of N3 (5-50mg/kg), Ganciclovir (GCV, 
10mg/kg), Foscarnet (PFA, 45-90mg/kg), or saline.  N3-50mg and GCV showed 
comparable reduction of salivary gland infectious virus titers 14 days post infection, 
while N3-5mg did not control virus titers.  Quantitative PCR (QRT-PCR) showed that 
GCV treatment reduced viral DNA load in salivary glands, but N3 did not.  Similarly, 
lungs showed no significant reduction in viral DNA load for N3-50mg.  In contrast, N3 
(all doses), PFA, and GCV similarly reduced hepatic viral DNA load compared to saline 
treated mice.  Taken together, these data suggest some in-vivo antiviral effect of the novel 
N3 compound.  Interestingly, in some tissues, N3 may inhibit viral growth without 
inhibiting DNA replication.  Overall poor effect of N3 in organs outside the peritoneal 
cavity suggests a problem with drug bioavailability when administered via the 
intraperitoneal route.  Further evaluation of N3 efficacy in-vivo and mechanism of action 
will be required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Cytomegalovirus (CMV) is a ubiquitous member of the beta-herpes virus family, 
infecting 60% of the US population by age 6, and nearly 90% during their lifetime (1).  
Although acute infection is common and usually controlled by the host, it does pose 
several threats.  CMV is the most common viral cause of congenital birth defects in the 
United States (1).  40,000 children each year are born with congenital CMV infection that 
can lead to hearing loss and mental retardation.  CMV is also of serious concern to 
immunosuppressed individuals (transplant, therapeutic, HIV, etc), causing CMV 
pneumonia, retinitis, gastroenteritis, encephalitis, disease similar to mononucleosis, and 
increased susceptibility to bacterial and fungal infection (2-4).  Prior to development of 
antiviral therapy, CMV was a leading cause of morbidity and mortality in these patient 
populations. 
Following primary infection, the virus enters a latent state that centers in myeloid 
progenitor cells of the bone marrow and, to a lesser extent, other tissues (5, 6).  During 
latency, viral DNA incorporates itself into host cells by forming and maintaining 
episomes.  CMV may exit latency by reactivation during times of immunosuppression.  
Once reactivated, disease can occur once again. 
Unfortunately, there are still numerous hurdles for therapy of CMV.  Unlike many 
other viruses, there are presently no effective vaccines that provide sterilizing immunity.  
Passive transfer using immunoglobulin from previously infected individuals has similarly 
failed to prevent infection (7).  Because current pharmacologic therapies target active 
virus, these therapies become ineffective once CMV infections become latent.  Thus, 
treatment is administered for severe primary infection, or for cases of viral reactivation. 
Although currently available antiviral treatments are often life-saving, all have 
drawbacks.  Ganciclovir (GCV) is the drug of choice for most CMV infections (8). GCV 
is a guanosine analog lacking a 3’OH that competitively incorporates into replicating 
viral DNA causing elongation disruption.  Prior to incorporation, GCV is activated by the 
kinase produced by human CMV (HCMV) gene, UL97 (a conserved kinase, M97 is 
present in mice).  Therapy with GCV does provide effective suppression of virus 
replication, but, in addition to the compound’s toxicity, widespread use has led to 
resistant strains (9).  Alteration of the UL97 kinase is often the cause of resistance (10).   
Foscarnet (phosphonoformic acid, PFA), an organic analog of inorganic 
pyrophosphate, is an alternative therapy to GCV (8).  PFA is another viral polymerase 
inhibitor that functions by blocking pyrophosphate loading of virally encoded DNA 
polymerase (product of gene UL54 in humans, M54 in mice).  It is not activated by UL97 
like GCV and therefore has activity against many GCV resistant strains.  Unfortunately, 
PFA is nephrotoxic at the effective dose of 90mg/kg, which limits PFA’s clinical utility.  
These shortcomings demand new antiviral development capable of treating 
resistant strains without nephrotoxicity.  It has been suggested that AZT, an antiviral 
thymidine analog, can be effectively used in some cases of CMV retinitis (11).  
Nonetheless, it is most often used in cases of HIV infection and there has been little study 
into its efficacy against CMV.  Prof Schott (University of Tübingen, Germany) has 
developed a novel duplex antiviral agent, designated N3 (fig. 1), which is a combination 
of PFA and AZT by glyceryllipid residue.  This duplex is intended to provide synergistic 
effect of AZT and PFA, reducing the amount of PFA needed by half and reducing the 
possibility of nephrotoxicity.  This novel compound has shown excellent in-vitro efficacy 
against CMV replication.  
It is our hypothesis that N3 has antiviral action against CMV in-vivo.  We utilized 
a murine model of CMV (MCMV) infection to investigate this hypothesis (12).  With 
development of any drug, toxicity must be explored first in non-human subjects if 
possible.  Because of ethical limitations, HCMV studies are difficult, and are often 
carried out using murine models due to similarities between the two CMV strains (13).  A 
primary infection model was chosen to keep experiments as simple as possible in the 
initial trial.  We hope to determine whether N3 is effective against MCMV in-vivo, and 
compare its effectiveness against GCV or PFA.  Proving in-vivo efficacy of N3 will be 
necessary before clinical trials can be performed to test effectiveness against HCMV.  
Thus, these studies are an important first step towards the potential development of N3 as 
an effective treatment for HCMV infections. 
 
Methods 
 
In-Vitro Efficacy of N3 for MCMV 
Cell culture-based experiments were used to examine the ability of N3 to inhibit 
viral DNA replication and to ensure activity against MCMV.  25, 50, 100, or 200µM 
doses of N3 were applied in a single dose to MCMV-infected NIH 3T3 fibroblasts.  
Infected cells were harvested at 24, 48, or 72hrs post infection and DNA was purified for 
quantitative real-time PCR (QRT-PCR) analysis of viral DNA content.  A second in-vitro 
experiment was conducted in similar fashion; in this case, two titers of virus, 5 X 101 
plaque forming units (PFU) per well and 5 X103 PFU/well, were dosed, and cell culture 
media was supplemented with a 100µM concentration of N3 and replaced daily with 
fresh media containing 100µM N3 prior to harvesting cells and purifying DNA.   
 
 
PCR and Quantitative PCR 
DNA was purified by QIAamp Tissue kits (QIAGEN GmbH, Hilden, Germany), 
eluted in 150µl of AE buffer (contained in the kit), and stored at -20°C until analysis.  
DNA was quantitated by measuring absorption at 260nm/280nm (A260/280) using a 
Beckman DU 640B spectrophotometer.  500ng of DNA was amplified in a total volume 
of 25µl with 200nM of each DNA primer, 200nM of gene-specific fluorescent probe, and 
12.5 of 2X Takara Premix Ex Taq (Roche Molecular Systems, Basel Switzerland).   
Primer sets and fluorescence resonance energy transfer type probes for MCMV 
glycoprotein B (gB) and beta actin (ß-actin) quantitation were designed for the Cepheid 
SmartCycler (San Diego California).  GB is a viral envelope protein that is always 
synthesized during MCMV replication.  ß-actin DNA was used as a cellular transcript 
control, since it is expressed at constant levels under many conditions, including virus 
replication.  During the single strand phase of PCR, the probe binds the complementary 
target sequence, and fluoresces.  This emission is measured by the optical receptors of the 
machine and recorded.  Once the emission intensity crosses a threshold preset to exclude 
random binding, the machine notes the number of cycles completed up to that point.  
Initial DNA quantity is inversely related to cycle count.   
QRT-PCR was performed under the following program: initial denaturation 10 
sec at 95°C, 50 cycles-denaturation 15s at 95°C, annealing 15s at 58°C with the optics on, 
and elongation 30s at 68°C.  The short initial denaturation step was chosen per 
manufacturer instruction to optimize fully the hot-start Taq included in the Takara mix.  
Plasmids homologous to the sequence amplified by our primers were cloned for both the 
gB and ß-actin genes, and using serial dilution of known plasmid concentrations, standard 
curves were constructed for quantification of products obtained by QRT-PCR.  
Regression equations had high R2 values (0.995 for gB and 0.997 for ß-actin), and were 
thus used for all subsequent copy number calculations.  Real time PCR results are 
expressed as copies of gB/10E4 copies of ß-actin for liver and lung results.  Salivary 
gland results are expressed in copies of gB/ß-actin   
 Sequences for real time primers/probes designed are as follows:  
Gene/Direction Forward reverse probe 
ß-actin attgtgatggactccggtga agctcatagctcttctccag caccacactgtcccatctac 
CMV gB tgtactcgaagggagagct cgttcaccaccgaagacac cgcctcgaacgtgttcagcctg
 
 
 
Infection Preparation 
Female BALB/c mice (Harlan, Indianapolis, IN) 6-8 weeks of age were used in 
this study.  Purified Smith strain MCMV was obtained from ATCC (Rockville, MD).  
Primary infection was achieved by intraperitoneal injection of mice with 5 X 104 PFU 
Smith strain MCMV.  Groups (n=5) were randomly assigned to receive saline, GCV 
10mg/kg/day, PFA 45 mg/kg/day, PFA 90 mg/kg/day, N3 5mg/kg/day, N3 10mg/kg/day, 
N3 25 mg/kg/day, or N3 50mg/kg/day.  All doses were administered in 0.2cc of saline.  A 
dose of 10mg/kg/day of GCV was chosen because this has been shown to be efficacious 
in preventing virus replication in mice (14).  Because 90mg/kg/day is the recommended 
dose of PFA (15); and because previous research has indicated the lethal dose of N3 in 
mice to be 100mg/kg (Schott, personal communication); a dose of 50mg/kg/day of N3 
was chosen to test whether a half dose of N3 is as effective as the standard dose of PFA.  
In addition, a series of lower N3 concentrations were also tested (see above). 
Antiviral treatment was initiated the day after infection and mice were weighed 
several times during the course of the experiment.  Frequent weighing was used as a 
measure of the drug’s general effects on the mice.  Mice were euthanized 14 days post-
infection by cervical dislocation under inhalation anesthesia.  To examine for antiviral 
effects on normal mouse kidney function, blood was collected to test for creatinine levels 
using an i-STAT (Heska Corporation, Friboug, Switzerland).  Creatinine, a by-product of 
creatine phosphate breakdown in the muscles, is filtered by the kidneys.  A high 
creatinine level in the blood would be an indication of renal toxicity.  Serum was 
extracted from the blood by centrifugation, flash frozen in liquid nitrogen, and then 
stored at -80°C.  Heart, lungs, salivary gland, spleen, liver, and kidneys were dissected 
aseptically and frozen in the same manner.  Small sections were removed from each 
organ at the time of dissection, preserved in 10% formalin, and embedded in paraffin 
blocks for histological analysis.  
 
 
In-Vitro Plaque Assay for Viral Quantitation 
To assess the presence of infectious virus, plaque assays were performed on 
salivary gland and lung homogenates.  Organ homogenates were made by removing a 
small sections, weighing them, and adding phosphate buffered saline (PBS) to create a 
5% (weight:volume) solution.  The organ and PBS solutions were then homogenized with 
an electric tissue homogenizer at 30,000 rpm.  Additionally, salivary gland homogenates 
were sonicated 4 times for 3 seconds to ensure cell lysis.  These lysates were clarified by 
centrifugation at 2000 rpm for 10 min, serially diluted in Dulbecco/Vogt Modified 
Eagle's Minimal Essential Medium (DMEM) plus 2% Newborn Calf Serum (NCS), and 
the supernatants placed on confluent monolayers of NIH 3T3 fibroblasts (ATCC) in six-
well plates (35 mm wells).  As a control for virus infection, an uninfected mock well was 
left on each plate.  Plates were subsequently centrifuged at 1220 rpm for 30min and 
incubated for 2 hours at 37°C.  After the incubation period, media was removed and 
replaced with DMEM containing 10% NCS and 1% low-melting agarose.  Once the agar 
had solidified, plates were incubated at 37°C/5% CO2 in cell culture incubators.  5 days 
post-infection, plates were fixed in 10% formalin.  Agar plugs were removed and plates 
were stained with crystal violet for enumeration.  Dilutions containing approximately 10-
100 plaques per well were used to determine virus titers.  All virus titers enumerations 
were performed in duplicate.   
  
 
Statistics 
Student’s T tests or Analysis of variance tests were performed using Graphpad software 
to ensure statistical significance. 
Results 
 
In-vitro Efficacy of N3 for MCMV 
Initial in-vitro experiments showed N3 to be ideally effective at 100µM; in contrast, 
200µM induced cellular cytotoxicity (cell lysis, data not shown).  When media and drug 
were not replaced after the initial addition, replication was inhibited most effectively on 
the first day (data not shown).  DNA levels steadily rose for subsequent days when 
infected cells were homogenized and viral DNA was quantified by QRT-PCR.  In 
contrast, viral DNA replication was inhibited when drug and media were replenished 
daily (fig. 2).  100µM N3 was shown to completely inhibit MCMV at 5 X 101 PFU and 
significantly reduce viral DNA load at 5 X 103 PFU, in comparison to untreated infected 
cells.   
 
 
General Response to N3 Compound 
Mice tolerated most doses of N3 well.  There were no noticeable side effects at 5, 10, or 
25mg/kg/day of N3.  At the highest dose of N3, 50mg/kg/day, subjects showed weight 
loss of approximately 8% total body weight (fig. 3) on average and appeared to have 
loose, shaggy coats.  The livers of mice in this group also displayed blanched regions and 
their behavior was hyperactive (characterized by frequent abnormally high jumping and 
overreaction to injection).  Creatinine testing showed no nephrotoxicity characteristic of 
PFA treatment.  Creatinine levels were normal for all groups.  Histology has not been 
completed at this time.  
 
 
Liver Viral Load 
QRT-PCR showed that viral DNA levels were reduced in the liver approximately eight-
fold with N3 treatments of 5, 10, 25, or 50 mg/kg/day, in comparison to untreated mice.  
This reduction was comparable to GCV in the liver (fig. 4).  An important note is that the 
lowest dose of N3, 5mg/kg/day, appeared to be as effective as GCV, PFA or any of the 
higher N3 concentrations.  ANOVA suggested that treatment groups had significantly 
lower viral DNA titers than saline controls (p=0.0001), and individual students t-tests 
comparing each treatment group to saline controls showed that titers were significantly 
lower for all treatment groups (p<0.05).  There were no significant differences between 
treatment group viral titers when compared individually. 
 
 
Lung Viral Load 
There was no significant difference between any treatment group and saline controls in 
lung viral DNA loads (p>0.05, fig. 5).  In addition, plaque assays of lung homogenates 
did not produce any viable counts of infectious virus.  This unexpected result suggests 
that low amounts of infectious virus made it into the lungs after infection,    
  
 
 
 
Salivary Gland Viral load 
Plaque assays showed N3 50 mg to have comparable efficacy in reducing infectious 
particle formation when compared to GCV; and both showed a ten-fold reduction in PFU 
compared with saline or N3 5mg (p<0.05, fig. 7).  Surprisingly, viral DNA load was not 
reduced in the salivary gland by N3 treatment, in contrast to GCV, which significantly 
reduced viral DNA load compared to saline controls (p<0.05, fig 6).  Viral DNA load 
data produced by QRT-PCR indicates the quantity of viral DNA present in the organ.  
Viral titers were somewhat higher than typical for MCMV, but the repeat data indicates 
log reductions that are in line with ten-fold dilution series prepared and run in duplicate.  
This would seem to indicate that the atypically high titers could be attributed to a 
repeatable and relative counting error by the researcher. 
 
 
 
Discussion 
 
 This study demonstrates that N3 is capable of inhibiting MCMV in-vitro, and 
suggests that it may be effective in-vivo.  Liver data indicate that N3 inhibits infectious 
virus particle titers and viral DNA load.  On the other hand, bioavailability appeared to be 
a problem in the lung and salivary gland.  Data for these organs did show some anti-viral 
effect, but, due to intraperitoneal dosing, it is not clear if N3 was active in these organs or 
just prevented spread of live virus to these organs from the original intraperitoneal 
infection location.  Nevertheless, it is our conclusion that N3 shows promise in the 
treatment of CMV infection and is worthy of future study. 
In-vitro experiments suggested N3 was effective against MCMV.  We found that 
100µM was the most effective in-vitro dose that did not cause cytotoxic effects to the 
fibroblasts.  We also demonstrated that in-vitro effectiveness of N3 decreases without 
replenishment in culture media.  When combined with data indicating reduction of viral 
load in the liver, we concluded that N3 has potential efficacy in-vitro and in-vivo against 
MCMV.  Furthermore, these experiments indicate that the mouse model is a viable route 
for future testing of N3 as a potential antiviral drug used to treat CMV infections.  
Our QRT-PCR results indicated that intraperitoneal dosing was effective in 
controlling virus replication in the liver.  An 8-fold reduction of viral load suggested that 
N3 is effective in inhibiting CMV replication in-vivo, even at low doses.  Unfortunately, 
N3 appears to show toxicity to the liver at the 50mg dose.  The blanched regions of the 
liver combined with the abnormal behavior of the mice receiving this N3 dose is not 
conclusive, but does suggest that 50mg/kg/day of N3 delivered intraperitoneally can 
cause liver damage.  Histologic evaluation may provide some insight into the effect on 
the liver, and other organs tested, even though other organs showed no gross 
abnormalities. 
 Although there was a trend toward efficacy of N3 inhibiting CMV replication in 
the lungs, with the most effective dose being 50mg/kg, these differences were not 
statistically significant.  This pulmonary effect might be a consequence of intraperitoneal 
N3 preventing spread of virus from the infection site.  There is no strong evidence yet 
that N3 reaches organs other than liver when administered intraperitoneally, but the effect 
of N3 in liver may be strong enough to preclude spread to these distant organs.  Similar 
effect was seen for intraperitoneal GCV and PFA, which did not show a significant effect 
in the lungs.  In some ways, this was poor experimental design, because it is well known 
that GCV and PFA are poorly available by any route other than intravenous.  Nonetheless, 
intraperitoneal control drugs were appropriate comparators for intraperitoneal N3, and 
measuring serum concentrations of N3 after intraperitoneal administration will help to 
answer this question. 
Salivary gland results also showed contradictory findings.  Plaque assay data 
indicated that N3 is capable of reducing viral titers comparable to GCV.  On the other 
hand, our QRT-PCR results imply that N3 is not inhibiting production of viral DNA.  
QRT-PCR does not discriminate between viable or nonviable virus, nor does it indicate if 
viable virus is capable of producing an infection.  Because in-vivo mechanisms of action 
of N3 have not been elucidated, it is possible that N3 controls MCMV by an additional 
mechanism other than inhibition of DNA replication.  It is also possible that like lungs, 
N3 is not reaching the salivary gland, due to first pass effect or poor bioavailability, and 
that the viral control seen here was again a consequence of prevention of dispersion of 
the infection beyond the liver.   
Bioavailability is a measure of the quantity of a compound that can reach end 
organs.  When administered via an intraperitoneal route, N3 may not have adequate 
bioavailability because it may be metabolized during passage through the hepatic portal 
system of the liver.  This “first-pass effect,” could result in extensive reduction of serum 
and distant tissue drug concentrations.  Previous studies have shown that blocking the 
free –COOH of N3 by an –OC2H5-ethyl ester group or blocking the pyrophosphate 
binding site of the viral polymerase would completely destroy antiviral activity of N3 in- 
vitro (Schott, personal communication).  This could be one of many possible mechanisms 
of hepatic metabolism.  Additional studies are necessary to discover the source of the 
reduction of N3 antiviral activity in distal organs.  The first and simplest study will be to 
measure N3 serum concentrations after 2 weeks of therapy.  In addition, experiments 
using alternate routes of administration are ongoing, and will hopefully demonstrate 
improved bioavailability and in-vivo effect. 
Future research will expectantly show that N3 has several possible uses.  In 
addition to in-vitro data suggesting efficacy against GCV resistant strains of CMV, N3 
may be valuable to HIV/CMV dually infected individuals.  In the dually infected patients, 
treatment of concomitant infections, such as herpes simplex virus, has been shown to 
reduce HIV-1 RNA levels (16).  The AZT subsection of the N3 molecule may provide 
concurrent action against HIV increasing overall utility of N3.  In theory, enzymatic 
cleavage should release several different antiviral metabolites e.g. AZT, Foscarnet, 
lipophilic AZT, and Foscarnet derivatives.  Lipid prodrugs of phosphonoacids like 1-O-
octadecyl-sn-gylcero-3-phosonoformate (to which N3 can be compared) have been 
shown to enhance antiviral activity of PFA in HIV, HSV, and HCMV-infected cells in-
vitro.  This is because of the increased uptake by host cells, where intracellular enzymes 
then convert prodrug to an active form (17).  Lipophilic AZT provides an added benefit 
in increased cellular membrane passage much like the lipid prodrug of PFA.  These 
products are beneficial to the action of the drug and could improve the overall efficacy of 
N3, despite the fact that N3 pharmacokinetics dominate the effects of any single 
compound.  This is advantageous since the drug is a 1:1 ratio of AZT to PFA; thus, half 
the quantity of PFA is delivered when compared to administration of pure PFA, which 
reduces the chances of the nephrotoxicity from higher doses.  
 Taken together, our results suggest that N3 is a potential antiviral agent for 
treatment of CMV infection.  Due to lack of evidence of systemic effect in our studies, 
investigations into bioavailability of N3 when administered by alternate routes will be 
required.  Future research will attempt to optimize dose ranges and delivery routes of N3 
to optimize efficacy of CMV inhibition.  Methods will be developed to measure serum 
concentrations and more effective routes of delivery will be explored, including 
subcutaneous, intravenous, and intramuscular injections.  These experiments will attempt 
to reduce possible toxic effects of N3 and ideally result in more widespread antiviral 
action.    
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Figure 1.  N3: 3’-Azido-2’,3’-didesoxy-thymidylyl(5’-2)-1-O-octadecyl-rac-glycerol-3-
(hydroxyxcxarbonyl)-phosphonate x3 Na  MW=781.34 A duplex antiviral candidate 
formed by Foscarnet and Zidovudine with a glyceryllipid backbone.  N3 is intended for 
treatment of Cytomegalovirus. 
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Figure 2.  In-vitro DNA replication inhibition by N3.  Confluent 3T3 fibroblasts were 
infected with MCMV at concentrations of either 5 X 103 PFU or 5 X 10-1 PFU and treated 
with 100µM of N3.  Fibroblasts were harvested at 24, 48, and 72hrs.  Samples were 
homogenized, viral DNA were purified, and quantitated with QRT-PCR.  N3 showed 
inhibition of viral DNA when compared to untreated cells. 
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Figure 3.  Weight change by group.  BALB/c mice were infected with CMV, treated with 
saline or antivirals.  Groups were weighed regularly to evaluate effects of N3 on general 
metabolism.  N3 at 50mg/kg/day caused an approximate 8% total body weight loss.  
Other groups (PFA, GCV, Saline) showed no significant changes in weight.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Viral DNA load in the Liver.  BALB/c mice were infected with CMV, treated 
with saline or antivirals, and their livers were harvested 14 days post-infection.  Samples 
were homogenized, DNA were purified, and quantitated with QRT-PCR.  ANOVA 
suggested that treatment groups had significantly lower DNA titers than saline controls 
(p=0.0001), and individual students t-tests comparing each treatment group to saline 
controls showed that titers were significantly lower for all treatment groups (p<0.05).  
Notably, a dose of 5mg/kg/day of the experimental drug, N3, was as effective in reducing 
viral load as GCV, PFA, and other higher concentrations of N3.   
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Figure 5.  Viral DNA load in the Lung.  BALB/c mice were infected with CMV, treated 
with saline or antivirals, and their lungs were harvested 14 days post-infection.  Samples 
were homogenized, DNA were purified, and quantitated with QRT-PCR.  N3 also 
appeared to have effects comparable to GCV in the lungs (p=0.48), as viral DNA quantity 
was reduced by half in comparison to untreated lungs.  There was no significant 
difference between any treatment group and saline controls in lung viral DNA loads 
(p>0.05).   
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Figure 6.  Viral DNA load in the salivary gland.  BALB/c mice were infected with CMV, 
treated with saline or antivirals, and their salivary glands were harvested 14 days post-
infection.  Samples were homogenized, DNA were purified, and quantitated with QRT-
PCR.  Individual students t-tests comparing each treatment group to saline controls 
showed that titers were significantly lower only for the GCV treatment group (p<0.05).  
The experimental drug, N3, appeared ineffective in reducing viral DNA load.  
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Figure 7.  IVPA of the salivary gland.  BALB/c mice were infected with MCMV, treated 
saline or antivirals, and salivary glands were harvested 14 days post infection.  Samples 
were homogenized and applied to confluent 3T3 fibroblasts in culture.  Plaque assays of 
N3 at 5mg/kg/day and 50mg/kg/day were compared to GCV and saline.  Plaque assays 
showed N3 50 mg to have comparable efficacy in reducing infectious particle formation 
when compared to GCV; and both showed a ten-fold reduction in PFU compared with 
saline or N3 5mg (p<0.05).  A low concentration of N3 (5mg/kg) was not effective in 
reducing infectious particle count. 
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